S-1: Genprex Registers 25M Shares for Resale Amid Nasdaq Delisting Threat

Genprex, a clinical-stage gene therapy company, filed an S-1 to register 25 million common shares for resale by Lincoln Park Capital Fund, LLC, while facing Nasdaq delisting for bid price and equity non-compliance.

Summary

• Genprex, Inc. filed an S-1 registration statement for the resale of up to 25,000,000 shares of common stock by Lincoln Park Capital Fund, LLC.
• The company entered into a Purchase Agreement with Lincoln Park on June 11, 2025, for up to $12.5 million in common stock sales, of which $2,460,136 has already been received.
• An additional $10,039,864 in gross proceeds may be received from future sales to Lincoln Park, at the company's discretion, over a 24-month period.
• Genprex is a clinical-stage gene therapy company with oncology (REQORSA for NSCLC, SCLC) and diabetes (GPX-002 for Type 1 and Type 2 diabetes) programs.
• The company is currently enrolling patients in the Phase 2a expansion of its Acclaim-1 trial (REQORSA + Tagrisso for NSCLC) and the Phase 2 expansion of its Acclaim-3 trial (REQORSA + Tecentriq for ES-SCLC).
• Enrollment for the Acclaim-2 trial (REQORSA + Keytruda for NSCLC) was ceased in August 2024 due to challenges.
• Genprex faces Nasdaq delisting threats due to non-compliance with the $1.00 minimum bid price requirement and the $2.5 million minimum stockholders' equity requirement (reported $1,391,195 as of June 30, 2025).
• The company has a history of operating losses and its auditor expressed "substantial doubt about our ability to continue as a going concern."
• A wholly-owned subsidiary, Convergen Biotech, Inc., was formed on February 18, 2025, to separate the diabetes clinical development program.
• Since December 31, 2024, Genprex sold 16,940,454 shares through its ATM program, generating $6,895,947 in net proceeds.

Sentiment

Score: 3

Explanation: While there are positive clinical developments (Fast Track, Orphan Drug, some promising early-stage patient data), these are overshadowed by severe financial distress, Nasdaq delisting threats, and a 'going concern' warning from auditors. The capital raise through Lincoln Park is a necessity rather than a sign of strength, and it comes with significant dilution. The cessation of a clinical trial also indicates operational challenges.

Positives

• REQORSA (Acclaim-1 trial) received FDA Fast Track Designation for NSCLC patients.
• REQORSA (Acclaim-3 trial) received FDA Fast Track Designation and Orphan Drug Designation for ES-SCLC.
• One patient in Acclaim-1 Phase 1 achieved partial remission and maintained it for approximately 36 months, continuing treatment.
• Preclinical data for GPX-002 (diabetes) in non-human primate models showed statistically significant improvements, including decreased insulin requirements, increased c-peptide levels, and improved glucose tolerance.
• Secured a commitment from Lincoln Park Capital Fund, LLC for up to $12.5 million in equity financing, providing a potential source of capital.
• Shareholder approval was obtained on August 15, 2025, for the Lincoln Park transaction, allowing issuance of shares exceeding the 19.99% threshold.

Negatives

• Facing Nasdaq delisting for failing to meet the $1.00 minimum bid price requirement and the $2.5 million minimum stockholders' equity requirement (reported $1,391,195 as of June 30, 2025).
• Independent auditor expressed "substantial doubt about our ability to continue as a going concern."
• History of operating losses since inception and expects further near-term losses.
• Ceased enrollment for the Acclaim-2 trial due to enrollment challenges and delays, indicating difficulties in clinical trial execution.
• The sale of common stock to Lincoln Park will cause substantial dilution to existing stockholders, with 25,000,000 shares representing approximately 37% of total outstanding shares.
• The company's ability to access the full $12.5 million from Lincoln Park is dependent on market price and other factors, and may not be fully realized.

Risks

• The sale of common stock to Lincoln Park may cause substantial dilution to existing stockholders, and the subsequent resale of these shares could cause the stock price to fall.
• There is a significant risk of delisting from Nasdaq due to non-compliance with the $1.00 minimum bid price and $2.5 million minimum stockholders' equity requirements, which could reduce liquidity and harm the ability to raise capital.
• The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern, indicating significant financial instability.
• The company may not have access to the full $12.5 million available under the Purchase Agreement with Lincoln Park, which could materially adversely affect liquidity.
• Investing in the company's common stock is highly speculative and involves a significant degree of risk, including the uncertainty of developing marketable products and obtaining regulatory approvals.
• The company operates in a very competitive and rapidly changing environment, facing competition from larger and/or better-financed biotechnology and pharmaceutical companies.
• Dependence on third-party suppliers or manufacturers to supply or manufacture key ingredients and products poses operational risks.
• There is a possibility that there may be no market acceptance for the company's products, even if approved.
• Changes in third-party reimbursement policies could adversely affect potential future sales of any approved products.

Future Outlook

The company expects to incur additional near-term operating losses and will need to raise substantial additional capital to fund operations and planned development. It anticipates completing enrollment for interim analysis in Acclaim-1 Phase 2a by Q1 2026, with interim analysis in H1 2026. For the diabetes program, it expects to seek further regulatory guidance from the FDA on IND-enabling studies in H2 2025 after additional nonclinical studies. The company intends to take definitive steps to regain and maintain compliance with Nasdaq listing requirements, including potentially considering a reverse stock split or raising additional capital.

Management Comments

• "We intend to continue to take definitive steps in an effort to evidence compliance with the Minimum Stockholders Equity Requirement, the Bid Price Requirement, and the other Nasdaq listing requirements."
• "However, there can be no assurance that the Panel will grant our request for continued listing or that we will be able to evidence compliance... or that we will be able to maintain compliance with the other Nasdaq listing requirements."
• "Although the Acclaim-2 study in patients progressing on Keytruda containing regimens has been closed due to, among other factors, slow enrollment, we continue to believe that this combination could be beneficial."

Industry Context

Genprex operates in the highly competitive and rapidly evolving gene therapy and oncology/diabetes treatment sectors. Its strategy involves developing REQORSA in combination with approved cancer drugs (Tagrisso, Tecentriq), indicating a focus on improving existing treatment paradigms rather than entirely novel first-line therapies. The cessation of the Acclaim-2 trial due to "competition for investigators and eligible patients with numerous other trials involving the same patient population" highlights the intense competitive landscape and resource constraints faced by smaller clinical-stage biotechs. The pursuit of both oncology and diabetes gene therapies suggests a diversified pipeline, but also potentially stretched resources. The reliance on academic collaborations (MD Anderson, University of Pittsburgh) is a common strategy for early-stage biotech companies to leverage research expertise.

Comparison to Industry Standards

• The company's stockholders' equity of $1.39 million is significantly below the Nasdaq minimum requirement of $2.5 million, indicating severe financial distress compared to established publicly traded companies.
• The stock bid price of $0.2917, well below the $1.00 Nasdaq minimum, is indicative of a micro-cap or penny stock, which typically carries higher risk compared to more stable, established biotech companies.
• The "going concern" qualification from auditors is a critical red flag, common for early-stage biotechs but still a severe indicator of financial instability compared to more mature industry players.
• The cessation of the Acclaim-2 trial due to "enrollment challenges and delays due to competition for investigators and eligible patients" suggests that Genprex struggles to compete for resources and patient recruitment against larger, better-funded pharmaceutical companies running similar trials (e.g., AstraZeneca, Merck, Genentech).
• While FDA Fast Track and Orphan Drug Designations are positive, aligning with industry efforts to accelerate development for unmet medical needs, they do not guarantee approval or commercial success, which is a standard risk in the biotech industry.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Significant dilution from the Lincoln Park transaction and potential future capital raises. Risk of delisting from Nasdaq could severely reduce liquidity and share price. The 'going concern' warning poses a substantial risk to their investment.
• **Employees**: Uncertainty regarding the company's financial stability and going concern status could negatively impact employee morale, retention, and future job security.
• **Customers/Patients**: Continued clinical trial progress (Acclaim-1, Acclaim-3) offers potential future treatment options, but delays and the cessation of Acclaim-2 highlight risks in bringing therapies to market, potentially impacting patient access to new treatments.
• **Creditors**: The 'going concern' warning and the ongoing need for additional financing indicate increased risk for creditors, potentially affecting the company's ability to meet its obligations.
• **Suppliers**: Dependence on third-party suppliers for manufacturing could be impacted by financial instability, potentially leading to disruptions in the supply chain for clinical trial materials.

Next Steps

• Continue enrolling and treating patients in Phase 2a expansion of Acclaim-1 clinical trial.
• Complete enrollment of first 19 patients for interim analysis in Acclaim-1 Phase 2a by Q1 2026.
• Conduct interim analysis for Acclaim-1 Phase 2a in H1 2026.
• Continue enrolling and treating patients in Phase 2 expansion of Acclaim-3 clinical trial.
• Complete enrollment of first 25 patients for interim analysis in Acclaim-3 Phase 2 by Q1 2026.
• Perform Phase 2 futility analysis for Acclaim-3 after 25th patient reaches 18 weeks of follow-up.
• Continue additional nonclinical studies for diabetes program (GPX-002).
• Initiate research in Type 2 diabetes animal models.
• Seek further regulatory guidance from FDA on IND-enabling studies for diabetes program in H2 2025.
• Attend Nasdaq Hearings Panel to request an extension and present a plan to regain compliance with listing requirements.
• Consider options such as a reverse stock split or raising additional capital to regain Nasdaq compliance.
• Potentially file additional registration statements to register more shares for resale by Lincoln Park if the full $12.5 million commitment is to be utilized.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a 'going concern' warning from its auditor and imminent Nasdaq delisting for failing to meet both minimum bid price and stockholders' equity requirements. While there are ongoing clinical trials and some positive early-stage data, these are overshadowed by the fundamental financial instability and operational challenges, including the cessation of a clinical trial due to enrollment issues. The current capital raise through Lincoln Park is highly dilutive and insufficient to resolve the long-term funding needs. The risk of delisting would further impair liquidity and investor confidence. Given these critical issues, the stock presents a high-risk profile with significant downside potential.

Keywords

Gene Therapy, Oncology, Diabetes, NSCLC, SCLC, REQORSA, GPX-002, Clinical Stage, Biotechnology, Nasdaq Delisting, Equity Financing, Dilution, SEC Filing, S-1, Lincoln Park Capital, Biopharma